1. Home
  2. FINS vs PGEN Comparison

FINS vs PGEN Comparison

Compare FINS & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FINS
  • PGEN
  • Stock Information
  • Founded
  • FINS 2019
  • PGEN 1998
  • Country
  • FINS United States
  • PGEN United States
  • Employees
  • FINS N/A
  • PGEN N/A
  • Industry
  • FINS Finance/Investors Services
  • PGEN Biotechnology: Pharmaceutical Preparations
  • Sector
  • FINS Finance
  • PGEN Health Care
  • Exchange
  • FINS Nasdaq
  • PGEN Nasdaq
  • Market Cap
  • FINS 447.8M
  • PGEN 493.0M
  • IPO Year
  • FINS N/A
  • PGEN N/A
  • Fundamental
  • Price
  • FINS $13.09
  • PGEN $4.01
  • Analyst Decision
  • FINS
  • PGEN Buy
  • Analyst Count
  • FINS 0
  • PGEN 5
  • Target Price
  • FINS N/A
  • PGEN $7.50
  • AVG Volume (30 Days)
  • FINS 78.0K
  • PGEN 5.0M
  • Earning Date
  • FINS 01-01-0001
  • PGEN 11-13-2025
  • Dividend Yield
  • FINS 9.97%
  • PGEN N/A
  • EPS Growth
  • FINS N/A
  • PGEN N/A
  • EPS
  • FINS N/A
  • PGEN N/A
  • Revenue
  • FINS N/A
  • PGEN $4,340,000.00
  • Revenue This Year
  • FINS N/A
  • PGEN $249.10
  • Revenue Next Year
  • FINS N/A
  • PGEN $710.03
  • P/E Ratio
  • FINS N/A
  • PGEN N/A
  • Revenue Growth
  • FINS N/A
  • PGEN N/A
  • 52 Week Low
  • FINS $11.61
  • PGEN $0.65
  • 52 Week High
  • FINS $12.57
  • PGEN $5.23
  • Technical
  • Relative Strength Index (RSI)
  • FINS 46.91
  • PGEN 55.69
  • Support Level
  • FINS $12.98
  • PGEN $3.96
  • Resistance Level
  • FINS $13.20
  • PGEN $4.52
  • Average True Range (ATR)
  • FINS 0.13
  • PGEN 0.30
  • MACD
  • FINS 0.00
  • PGEN 0.05
  • Stochastic Oscillator
  • FINS 50.57
  • PGEN 64.92

About FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest

Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Share on Social Networks: